Upsher-Smith Laboratories, Inc.

194 articles with Upsher-Smith Laboratories, Inc.

• Upsher-Smith Partners With Cove To Expand Access To Its Migraine Medication Tosymra® (Sumatriptan Nasal Spray) 10 mg

  9/14/2021

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its partnership with Cove, a telemedicine company focused entirely on migraine.

• Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP

  8/16/2021

   Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Carbamazepine Extended-Release Tablets, USP in 100 mg, 200 mg and 400 mg strengths.

• Upsher-Smith Launches Isotretinoin Capsules

  6/25/2021

   Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Isotretinoin Capsules.

• Upsher-Smith And The National Alliance Of State Pharmacy Associations (NASPA) Honor 42 U.S. Pharmacists For Their Excellence In Innovation

  2/8/2021

  Upsher-Smith Laboratories, LLC and the National Alliance of State Pharmacy Associations are pleased to honor the 2020 NASPA Excellence in Innovation Award recipients.

• Migraine Patients With High-Deductible Commercial Healthcare Plans To Benefit From Upsher-Smith's Expanded Access Pathways Program

  2/1/2021

  Now Offers Commercially Insured Patients $0 Copay and Free Home Delivery for Acute and Preventive Migraine Treatment Options

• Upsher-Smith Launches Ramelteon Tablets

  12/15/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Ramelteon Tablets, 8 mg. Upsher-Smith's product is AB-rated to the branded product, ROZEREM ® (ramelteon) tablets.* Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.

• Upsher-Smith Reimagines Prescriber Education With Launch Of Migraine PeerConnect

  12/7/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that as part of its ongoing effort to reimagine prescriber education during the COVID-19 pandemic, it has launched a new and innovative peer-to-peer product education program entitled Migraine PeerConnect.

• Upsher-Smith Supports The American Headache Society's Virtual 2020 Scottsdale Headache Symposium® As Gold Level Sponsor

  11/16/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the American Headache Society's 2020 Scottsdale Headache Symposium® as a Gold Level Sponsor. Due to the COVID-19 pandemic

• Amina Abubakar Of Charlotte, North Carolina Named 2020 Willard B. Simmons Independent Pharmacist Of The Year

  10/19/2020

  Known as the "Mother Theresa of Healthcare", Abubakar Earns Award for Tireless Service to Community Health and Advancing Pharmacy Education

• Upsher-Smith's Brad Leonard And Amy Dearborn Honored By Cardinal Health For Outstanding Service

  10/16/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that two of its employees have received top honors from Cardinal Health for their outstanding service and performance for the previous year. Brad Leonard ,

• Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection

  8/7/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) and AmbioPharm, Inc. (AmbioPharm) today announced that the companies have entered into a partnership agreement to develop and market Corticotropin Injection in the U.S. The market for adrenocorticotropic hormone or ACTH (brand Acthar ® Gel*) is currently

• Upsher-Smith Launches Propafenone Hydrochloride Extended-Release Capsules

  6/30/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Propafenone Hydrochloride Extended-Release Capsules in 225 mg, 325 mg and 425 mg strengths

• Upsher-Smith Offers Help To People With Migraines During National Migraine And Headache Awareness Month

  6/23/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its continued commitment to people who suffer from migraines during National Migraine & Headache Awareness Month (MHAM). The COVID-19 pandemic has made it

• Upsher-Smith Launches Ethacrynic Acid Tablets, USP

  6/23/2020

   Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Ethacrynic Acid Tablets, USP in 25 mg strength.

• Cipher Pharmaceuticals Receives Positive Ruling on Binding Arbitration with Upsher-Smith Laboratories

  4/20/2020

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the Company has been successful in its binding arbitration with Upsher-Smith Laboratories LLC ("Upsher-Smith").

• Upsher-Smith Kicks Off 2020 With Three Generic Product Launches

  2/19/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its generic portfolio with the recent launch of three new products: Fluvoxamine Maleate Tablets, Haloperidol Tablets, USP, and Clonidine Hydrochloride Extended-Release Tablets

• Upsher-Smith And The National Alliance Of State Pharmacy Associations (NASPA) Recognize 44 U.S. Pharmacists With Excellence In Innovation Award

  2/18/2020

  Awardees Selected for Their Commitment to Patients and Effort in Advancing the Pharmacy Profession

• Upsher-Smith Launches Clonidine Hydrochloride Extended-Release Tablets

  1/28/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Clonidine Hydrochloride Extended-Release Tablets in 0.1 mg strength. Upsher-Smith's product is AB1-rated to the branded product, KAPVAY® (clonidine hydrochloride) extended-release tablets

• Upsher-Smith Launches Fluvoxamine Maleate Tablets

  1/10/2020

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluvoxamine Maleate Tablets in 25 mg, 50 mg and 100 mg strengths.

• Upsher-Smith To Attend 2019 Annual Meeting Of The American Epilepsy Society

  12/6/2019

  Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 2019 Annual Meeting of the American Epilepsy Society (AES) December 6-10, 2019 in Baltimore, MD